Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 4/20 | 0.32 |
| ▸ | HTR2B | P41595 | 3/20 | 0.32 |
| ▸ | HTR2C | P28335 | 3/20 | 0.32 |
| ▸ | PTGFR | P43088 | 2/20 | 0.31 |
| ▸ | PTGER3 | P43115 | 2/20 | 0.31 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.31 |
| ▸ | HTR1A | P08908 | 1/20 | 0.31 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.31 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.31 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.31 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12759145 | 0.97 | HTR2C (0.33) | HTR2AHTR2BHTR2CPTGFRPTGER3 | |
| SCHEMBL12759181 | 0.96 | HTR2A (0.31) | HTR2AHTR2BHTR2CADRB2HTR1A | |
| SCHEMBL12759160 | 0.94 | HTR2A (0.32) | HTR2AHTR2BHTR2CPTGFRPTGER3 | |
| SCHEMBL22277315 | 0.94 | ADRB2 (0.31) | HTR2AHTR2BADRB2HTR1ASLC6A2 | |
| SCHEMBL12759153 | 0.94 | HTR2C (0.31) | HTR2AHTR2BHTR2CPTGFRPTGER3 | |
| SCHEMBL12759139 | 0.94 | PDE4B (0.33) | HTR2AHTR2BHTR2CPTGFRPTGER3 | |
| SCHEMBL12759182 | 0.92 | HTR2A (0.32) | HTR2AHTR2BHTR2CPTGFRPTGER3 | |
| SCHEMBL12759144 | 0.92 | HTR2C (0.34) | HTR2AHTR2BHTR2CADRB2HTR1A | |
| SCHEMBL12759159 | 0.91 | HTR2A (0.32) | HTR2AHTR2BHTR2CPTGFRPTGER3 | |
| SCHEMBL12760335 | 0.91 | HTR2C (0.33) | HTR2AHTR2BHTR2CADRB2HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2272837-B1 | LIQUID CRYSTALLINE COMPOUND WITH NEGATIVE DIELECTRIC ANISOTROPY, LIQUID CRYSTAL COMPOSITION, AND LIQUID CRYSTAL DISPLAY DEVICE | JNC CORP (JP) | 2014-12-17 | — | — | EP | disclosed |
| US-7914862-B2 | Liquid crystal compound having negative dielectric anisotropy, liquid crystal composition, and liquid crystal display device | CHISSO CORPORATION (JP) | 2011-03-29 | — | — | US | disclosed |
| US-7914862-B2 | Liquid crystal compound having negative dielectric anisotropy, liquid crystal composition, and liquid crystal display device | CHISSO CORPORATION (JP) | 2011-03-29 | — | — | US | disclosed |
| EP-2272837-A1 | LIQUID CRYSTALLINE COMPOUND WITH NEGATIVE DIELECTRIC ANISOTROPY, LIQUID CRYSTAL COMPOSITION, AND LIQUID CRYSTAL DISPLAY DEVICE | Chisso Corporation (JP) | 2011-01-12 | — | — | EP | disclosed |
| US-20090278088-A1 | LIQUID CRYSTAL COMPOUND HAVING NEGATIVE DIELECTRIC ANISOTROPY, LIQUID CRYSTAL COMPOSITION, AND LIQUID CRYSTAL DISPLAY DEVICE | CHISSO CORPORATION (JP) | 2009-11-12 | — | — | US | disclosed |
| US-20090278088-A1 | LIQUID CRYSTAL COMPOUND HAVING NEGATIVE DIELECTRIC ANISOTROPY, LIQUID CRYSTAL COMPOSITION, AND LIQUID CRYSTAL DISPLAY DEVICE | CHISSO CORPORATION (JP) | 2009-11-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090278088-A1 | LIQUID CRYSTAL COMPOUND HAVING NEGATIVE DIELECTRIC ANISOTROPY, LIQUID CRYSTAL COMPOSITION, AND LIQUID CRYSTAL DISPLAY DEVICE | OCIAD2, OCIAD1, CCDC22 | HTR2A 1041/4885HTR2B 2435/4885HTR2C 657/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.